Niki BioSolutions, Inc. (NasdaqCM: NIKI)
Health Care · Biotechnology · US
$—
— today · — 1Y
Niki BioSolutions, Inc. (NasdaqCM: NIKI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $25.21M and employs 1 people.
trading between 6.00 and 26.50.
Tweenvest scores Niki BioSolutions, Inc. across four factors: quality 31/100. Its strongest factor is quality.
NIKI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.21M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.86
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $26.50
- 52-week low
- $6.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.94M
- Employees
- 1
- Next earnings
- —
About Niki BioSolutions, Inc.
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
- ISIN
- KYG6096M1226
- Founded
- 2010
- Listed since
- Jul 20, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.